Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival

Executive Summary

Uncertainty about US FDA's direction under the new president may have spurred staff to ensure views on several issues released before administration changed.


Related Content

Trump Takes Office, Change At US FDA Arrives With ‘Beachhead Teams’
Industry Communications With Payors: US FDA Okays Info On Investigational Drugs
Make Interchangeability Great Again: Biosimilar Switching Studies Need US Comparators
'Safe Harbor' For Preapproval Information Exchange To Get Legislative Push
Biological Product Suffix Submissions Limited To 10 Candidates By US FDA
FDA Passes The Buck On LDTs, But Floats Ideas
US FDA Might Be Temporarily Headed By Ostroff As Califf Sets His Departure
Woodcock Tries To Calm US FDA Staff Fears About Trump
What's Next For LDTs? FDA May Be Eyeing A New Game Plan
FDA Feels Heat On Drug Pricing And Generic Labeling Rule





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts